3 Biotech Stocks to Steer Clear of
Sometimes it can be just as important to know which stocks you shouldn't buy as it is to know which ones you should. To help you separate the good from the bad, we asked a team of Fools to highlight a healthcare stock they think should be avoided. Read on to see what they said.
Big challenge approaching
Todd Campbell: GlaxoSmithKline PLC's 5% dividend yield may have you thinking that it's worth stashing in your portfolio, but fast-approaching competition for its best-selling drug, Advair, makes it too risky for my money.
Big challenge approaching
Todd Campbell: GlaxoSmithKline PLC's 5% dividend yield may have you thinking that it's worth stashing in your portfolio, but fast-approaching competition for its best-selling drug, Advair, makes it too risky for my money.